Nonmelanoma skin cancer

Clinical and Basic Immunodermatology

Volumn , Issue , 2008, Pages 223-243

  Moloney, Fergal J ^a   Halliday, Gary M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957618190     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84800-165-7_16     Document Type: Chapter

References (155)

1. Boukamp P. Non-melanoma skin cancer: What drives tumor development and progression? Carcinogenesis 2005;26(10):1657-67
2. Rehman I, Quinn AG, Healy E, Rees JL. High frequency of loss of heterozygosity in actinic keratoses, a usually benign disease. Lancet 1994;344(8925): 788-9
3. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br J Dermatol 1999;141(3):415-23
4. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992;26(6):976-90
5. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006;155(1):9-22
6. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993;329(16):1147-51
7. Brown EE, Whitby D, Vitale F, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer 2006;107(9):2282-90
8. Buell JF, Trofe J, Hanaway MJ, et al. Immunosuppression and Merkel cell cancer. Transplant Proc 2002;34(5):1780-1
9. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-Transplant recipients. N Engl J Med 2005;352(13):1317-23
10. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B Biol 2001;63(1-3):8-18
11. Bruls WA, Slaper H, van Der Leun JC, Berrens L. Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths. Photochem Photobiol 1984;40(4):485-94
12. Lim HW, Naylor M, Honigsmann H, et al. American Academy of Dermatology Consensus Conference on UVA protection of sunscreens: Summary and recommendations. J Am Acad Dermatol 2001;44(3):505-8
13. Setlow RB. Shedding light on proteins, nucleic acids, cells, humans and fish. Mutat Res 2002;511(1):1-14
14. Wikonkal NM, Brash DE. Ultraviolet radiation induced signature mutations in photocarcinogenesis. J Invest Dermatol Symp Proc 1999;4(1):6-10
15. Mouret S, Baudouin C, Charveron M, Favier A, Cadet J, Douki T. Cyclobutane pyrimidine dimers are predominant DNA lesions in whole human skin exposed to UVA radiation. Proc Natl Acad Sci USA 2006;103(37):13765-70
16. Kawanishi S, Hiraku Y, Oikawa S. Mechanism of guanine-specific DNA damage by oxidative stress and its role in carcinogenesis and aging. Mutat Res 2001;488(1):65-76
17. Halliday GM. Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat Res 2005;571(1-2):107-20
18. Pattison DI, Davies MJ. Actions of ultraviolet light on cellular structures. In: Cancer: Cell Structures, Carcinogens and Genomic Instability. Basel: Birkhauser Verlag AG, 2006:131-57
19. Agar NS, Halliday GM, Barnetson RS, Ananthaswamy HN, Wheeler M, Jones AM. The basal layer in human squamous tumors harbors more UVA than UVB fingerprint mutations: A role for UVA in human skin carcinogenesis. Proc Natl Acad Sci USA 2004;101(14):4954-9
20. Halliday GM, Agar NS, Barnetson RSC, Ananthaswamy HN, Jones AM. UV-A fingerprint mutations in human skin cancer. Photochem Photobiol 2005;81(1):3-8
21. He YY, Pi J, Huang JL, Diwan BA, Waalkes MP, Chignell CF. Chronic UVA irradiation of human HaCaT keratinocytes induces malignant transformation associated with acquired apoptotic resistance. Oncogene 2006;25(26):3680-8
22. Berking C, Takemoto R, Binder RL, et al. Photocarcinogenesis in human adult skin grafts. Carcinogenesis 2002;23(1):181-7
23. Damian DL, Barnetson RS, Halliday GM. Low-dose UVA and UVB have different time courses for suppression of contact hypersensitivity to a recall antigen in humans. J Invest Dermatol 1999;112(6):939-44
24. Fourtanier A, Moyal D, Maccario J, et al. Measurement of sunscreen immune protection factors in humans: A consensus paper. J Invest Dermatol 2005;125(3):403-9
25. Moyal DD, Fourtanier AM. Broad-spectrum sunscreens provide better protection from the suppression of the elicitation phase of delayed-Type hypersensitivity response in humans. J Invest Dermatol 2001;117(5):1186-92
26. Poon TSC, Barnetson RSC, Halliday GM. Sunlightinduced immunosuppression in humans is initially because of UVB, then UVA, followed by interactive effects. J Invest Dermatol 2005;125(4):840-6
27. Fisher MS, Kripke ML. Suppressor T lymphocytes control the development of primary skin cancers in ultraviolet-irradiated mice. Science 1982;216:1133-4
28. Kripke ML. Immunologic unresponsiveness induced by UV radiation. Immunol Rev 1984;80:87-102
29. Sluyter R, Halliday GM. Enhanced tumor growth in UV-irradiated skin is associated with an influx of inflammatory cells into the epidermis. Carcinogenesis 2000;21(10):1801-7
30. Byrne SN, Halliday GM. Dendritic cells: Making progress with tumour regression? Immunol Cell Biol 2002;80(6):520-30
31. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nature Rev Immunol 2007;7(1):19-30
32. Halliday GM. Skin immunity and melanoma development. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of melanoma. London: Martin Dunitz, 2004:25-42
33. Weninger W, Crowley MA, Manjunath N, von Andrian UH. Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med 2001;194(7):953-66
34. von Andrian UH, Mackay CR. Advances in immunology: T-cell function and migration-Two sides of the same coin [Review]. N Engl J Med 2000;343(14):1020-33
35. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: Incidence. J Am Acad Dermatol 1994;30(5 pt 1):774-8
36. Vitaliano PP. The use of logistic regression for modelling risk factors: With application to non-melanoma skin cancer. Am J Epidemiol 1978;108(5):402-14
37. Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. DNA repair and aging in basal cell carcinoma: A molecular epidemiology study. Proc Natl Acad Sci USA 1993;90(4):1614-8
38. Bergfelt L. UV-related skin conditions and Langerhans' cell populations in human skin. Acta Derm Venereol 1993;73(3):194-6
39. Grewe M. Chronological ageing and photoageing of dendritic cells. Clin Exp Dermatol 2001;26(7):608-12
40. Thivolet J, Nicolas JF. Skin ageing and immune competence. Br J Dermatol 1990;122 Suppl 35:77-81
41. Lejeune FJ. Epidemiology and etiology of malignant melanoma. Biomed Pharmacother 1986;40(3):91-9
42. Rees JL. The melanocortin 1 receptor (MC1R): More than just red hair. Pigment Cell Res 2000;13(3):135-40
43. Kelly DA, Young AR, McGregor JM, Seed PT, Potten CS, Walker SL. Sensitivity to sunburn is associated with susceptibility to ultraviolet radiation-induced suppression of cutaneous cell-mediated immunity. J Exp Med 2000;191(3):561-6
44. Franceschi S, Levi F, Randimbison L, La Vecchia C. Site distribution of different types of skin cancer: New aetiological clues. Int J Cancer 1996;67(1):24-8
45. Raasch B, Maclennan R, Wronski I, Robertson I. Body site specific incidence of basal and squamous cell carcinoma in an exposed population, Townsville, Australia. Mutat Res 1998;422(1):101-6
46. Moloney FJ, Comber H, O'Lorcain P, O'Kelly P, Conlon PJ, Murphy GM. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006;154(3):498-504
47. Jablonska S, Majewski S. Epidermodysplasia verruciformis: Immunological and clinical aspects. Curr Top Microbiol Immunol 1994;186:157-75
48. Boxman IL, Mulder LH, Noya F, et al. Transduction of the E6 and E7 genes of epidermodysplasiaverruciformis-Associated human papillomaviruses alters human keratinocyte growth and differentiation in organotypic cultures. J Invest Dermatol 2001;117(6):1397-404
49. Karagas MR, Nelson HH, Sehr P, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006;98(6):389-95
50. Hazard K, Karlsson A, Andersson K, Ekberg H, Dillner J, Forslund O. Cutaneous human papillomaviruses persist on healthy skin. J Invest Dermatol 2006
51. Harwood CA, Surentheran T, Sasieni P, et al. Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br J Dermatol 2004;150(5):949-57
52. Caldeira S, Zehbe I, Accardi R, et al. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol 2003;77(3):2195-206
53. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002;138(6):758-63
54. Wolf P, Nghiem DX, Walterscheid JP, et al. Plateletactivating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis. Am J Pathol 2006;169(3):795-805
55. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-Analysis. Arch Dermatol 1998;134(12):1582-5
56. Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: A review of the literature. Int J Dermatol 2005;44(5):355-60
57. Man I, Crombie IK, Dawe RS, Ibbotson SH, Ferguson J. The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy: Early follow-up data. Br J Dermatol 2005;152(4):755-7
58. Buell JF, Hanaway MJ, Thomas M, Alloway RR, Woodle ES. Skin cancer following transplantation: The Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005;37(2):962-3
59. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-Associated immunosuppressants. Arch Dermatol 2001;137(4):459-63
60. Otley CC, Maragh SL. Reduction of immunosuppression for transplant-Associated skin cancer: Rationale and evidence of efficacy. Dermatol Surg 2005;31(2):163-8
61. Moloney FJ, Kelly PO, Kay EW, Conlon P, Murphy GM. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg 2004;30(4 pt 2):674-8
62. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73(10):1565-72
63. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-Treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004;18(4):446-9
64. Bergfelt L. Langerhans cells, immunomodulation and skin lesions. A quantitative, morphological and clinical study. Acta Derm Venereol Suppl (Stockh) 1993;180:1-37
65. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-Autonomous mechanism. Nature 1999;397(6719):530-4
66. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003;76(3):597-602
67. Yarosh DB, Pena AV, Nay SL, Canning MT, Brown DA. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005;125(5):1020-5
68. O'Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309(5742):1871-4
69. Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 1974;53:1333-6
70. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: The case for conservative management. Br J Dermatol 1986;115(6):649-55
71. Curson C, Weedon D. Spontaneous regression in basal cell carcinomas. J Cutan Pathol 1979;6(5):432-7
72. Hunt MJ, Halliday GM, Weedon D, Cooke BE, Barnetson RS. Regression in basal cell carcinoma: An immunohistochemical analysis. Br J Dermatol 1994;130(1):1-8
73. Halliday GM, Patel A, Hunt MJ, Tefany FJ, Barnetson RSC. Spontaneous regression of human melanoma/ non-melanoma skin cancer: Association with infiltrating CD4+ T cells. World J Surg 1995;19(3):352-8
74. Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptidebased vaccination. Cancer Immunol Immunother 2004;53(3):249-55
75. Speiser DE, Pittet MJ, Rimoldi D, et al. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol 2003;13(6):461-72
76. Caignard A, Dietrich PY, Morand V, et al. Evidence for T-cell clonal expansion in a patient with squamous cell carcinoma of the head and neck. Cancer Res 1994;54(5):1292-7
77. Ohmen JD, Moy RL, Zovich D, et al. Selective accumulation of T cells according to T-cell receptor V beta gene usage in skin cancer. J Invest Dermatol 1994;103(6):751-7
78. Gaugler B, Vandeneynde B, Vanderbruggen P, et al. Human gene Mage-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179(3):921-30
79. Kato H. Expression and function of squamous cell carcinoma antigen. Anticancer Res 1996;16(4B): 2149-53
80. Torre GC. SCC antigen in malignant and non malignant squamous lesions. Tumor Biol 1998;19(6):517-26
81. Cataltepe S, Gornstein ER, Schick C, et al. Coexpression of the squamous cell carcinoma antigens 1 and 2 in normal adult human tissues and squamous cell carcinomas. J Histochem Cytochem 2000;48(1):113-22
82. Suminami Y, Nagashima S, Vujanovic NL, Hirabayashi K, Kato H, Whiteside TL. Inhibition of apoptosis in human tumour cells by the tumour-Associated serpin, SCC antigen-1. Br J Cancer 2000;82(4):981-9
83. Cavanagh LL, Halliday GM. Dendritic epidermal T cells in ultraviolet-irradiated skin enhance skin tumor growth by inhibiting Cd4(+) T-cell-mediated immunity. Cancer Res 1996;56(11):2607-15
84. Deng JS, Brod BA, Saito R, Tharp MD. Immuneassociated cells in basal cell carcinomas of skin. J Cutan Pathol 1996;23(2):140-6
85. Gelb AB, Smoller BR, Warnke RA, Picker LJ. Lymphocytes infiltrating primary cutaneous neoplasms selectively express the cutaneous lymphocyte-Associated antigen (CLA). Am J Pathol 1993;142(5):1556-64
86. Garciaplata D, Mozos E, Carrasco L, Solana R. HLA molecule expression in cutaneous squamous cell carcinomas-An immunopathological study and clinical-immunohistopathological correlations. Histol Histopathol 1993;8(2):219-26
87. Patel A, Halliday GM, Cooke BE, Barnetson RS. Evidence that regression in keratoacanthoma is immunologically mediated: A comparison with squamous cell carcinoma. Br J Dermatol 1994;131(6):789-98
88. Markey AC, Churchill LJ, Allen MH, MacDonald DM. Activation and inducer subset phenotype of the lymphocytic infiltrate around epidermally derived tumors. J Am Acad Dermatol 1990;23(2 pt 1):214-20
89. Myskowski PL, Safai B. The immunology of basal cell carcinoma. Int J Dermatol 1988;27(9):601-7
90. Wong DA, Bishop GA, Lowes MA, Cooke B, Barnetson RS, Halliday GM. Cytokine profiles in spontaneously regressing basal cell carcinomas. Br J Dermatol 2000;143(1):91-8
91. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10(5):588-94
92. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nature Immunol 2001;2(4):293-9
93. Sutton VR, Davis JE, Cancilla M, et al. Initiation of apoptosis by granzyme B requires direct cleavage of Bid, but not direct granzyme B-mediated caspase activation. J Exp Med 2000;192(10):1403-13
94. Deng JS, Falo LD, Kim B, Abell E. Cytotoxic T cells in basal cell carcinomas of skin. Am J Dermatopathol 1998;20(2):143-6
95. Melnikova VO, Ananthaswamy HN. Cellular and molecular events leading to the development of skin cancer. Mutat Res 2005;571(1-2):91-106
96. Boldrini L, Loggini B, Gisfredi S, et al. Mutations of Fas (APO-1/CD95) and p53 genes in nonmelanoma skin cancer. J Cutan Med Surg 2003;7(2):112-8
97. Satchell AC, Barnetson RS, Halliday GM. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma. Br J Dermatol 2004;151(1):42-9
98. Dorothee G, Vergnon I, Menez J, et al. Tumorinfiltrating CD4(+) T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: Role of IFNalpha on APO2L/TRAIL expression and -mediated cytotoxicity. J Immunol 2002;169(2):809-17
99. Grimbaldeston MA, Skov L, Finlay-Jones JJ, Hart PH. Increased dermal mast cell prevalence and susceptibility to development of basal cell carcinoma in humans. Methods 2002;28(1):90-6
100. Czarnecki D, Zalcberg J, Kulinskaya E, Kay T. Impaired cell-mediated immunity of apparently normal patients who had multiple skin cancers. Cancer 1995;76(2):228-31
101. Yamamura M, Modlin RL, Ohmen JD, Moy RL. Local Expression of Antiinflammatory Cytokines in Cancer. J Clin Invest 1993;91(3):1005-10
102. Kim J, Modlin RL, Moy RL, et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 1995;155:2240-7
103. Gutierrezsteil C, Wronesmith T, Sun XM, Krueger JG, Coven T, Nickoloff BJ. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-b- irradiated psoriatic plaques express Fas ligand (Cd95l). J Clin Invest 1998;101(1):33-9
104. Byrne SN, Halliday GM. High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4(+) T cell infiltration, enables murine skin tumours to progress. Cancer Immunol Immunother 2003;52:396-402
105. Nestle FO, Burg G, Fah J, Wronesmith T, Nickoloff BJ. Human sunlight-induced basal-cell-carcinomaassociated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol 1997;150(2): 641-51
106. Byrne SN, Halliday GM. Phagocytosis by dendritic cells rather than MHC II high macrophages is associated with skin tumour regression. Int J Cancer 2003;106(5):736-44
107. Halliday GM, Le S. Transforming growth factorbeta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin. Int Immunol 2001;13(9):1147-54
108. Weber F, Byrne SN, Le S, et al. Transforming growth factor-beta(1) immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. Cancer Immunol Immunother 2005;54(9):898-906
109. Diamond TH, Eisman JA, Mason RS, et al. Vitamin D and adult bone health in Australia and New Zealand: A position statement. Med J Aust 2005;182(6):281-5
110. Wong G, Gupta R, Dixon KM, et al. 1,25-dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J Steroid Biochem Mol Biol 2004;89-90(1-5):567-70
111. Dixon KM, Deo SS, Wong G, et al. Skin cancer prevention: A possible role of 1,25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol 2005;97(1-2):137-43
112. Kricker A, Armstrong B. Does sunlight have a beneficial influence on certain cancers? Prog Biophys Mol Biol 2006;92(1):132-9
113. Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: A randomised controlled trial. Lancet 1999;354(9180):723-9
114. Anders A, Altheide HJ, Knalmann M, Tronnier H. Action spectrum for erythema in humans investigated with dye lasers. Photochem Photobiol 1995;61(2):200-5
115. Poon TSC, Barnetson RS, Halliday GM. Prevention of immunosuppression by sunscreens in humans is unrelated to protection from erythema and dependent on protection from ultraviolet A in the face of constant ultraviolet B protection. J Invest Dermatol 2003;121(1):184-90
116. Damian DL, Halliday GM, Barnetson RS. Broadspectrum sunscreens provide greater protection against ultraviolet-radiation-induced suppression of contact hypersensitivity to a recall antigen in humans. J Invest Dermatol 1997;109(2):146-51
117. Fourtanier A, Gueniche A, Compan D, Walker SL, Young AR. Improved protection against solar-simulated radiation-induced immunosuppression by a sunscreen with enhanced ultraviolet A protection. J Invest Dermatol 2000;114(4):620-7
118. Wolf P, Hoffmann C, Quehenberger F, Grinschgl S, Kerl H. Immune protection factors of chemical sunscreens measured in the local contact hypersensitivity model in humans. J Invest Dermatol 2003;121(5):1080-7
119. Kelly DA, Seed PT, Young AR, Walker SL. A commercial sunscreen's protection against ultraviolet radiation-induced immunosuppression is more than 50% lower than protection against sunburn in humans. J Invest Dermatol 2003;120(1):65-71
120. Baron ED, Fourtanier A, Compan D, Medaisko C, Cooper KD, Stevens SR. High ultraviolet A protection affords greater immune protection confirming that ultraviolet A contributes to photoimmunosuppression in humans. J Invest Dermatol 2003;121(4):869-75;.
121. Halliday GM, Robertson BO, Barnetson RS. Topical retinoic acid enhances, and a dark tan protects, from subedemal solar-simulated photocarcinogenesis. J Invest Dermatol 2000;114(5):923-7
122. Barnetson RS, Ooi TKT, Zhuang LQ, et al. Nle(4)-D-Phe(7) -Alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006;126(8):1869-78
123. Arad S, Konnikov N, Goukassian DA, Gilchrest BA. T-oligos augment UV-induced protective responses in human skin. FASEB J 2006;20(11):U95-U105
124. Kripke ML, Cox PA, Alas LG, Yarosh DB. Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice. Proc Natl Acad Sci USA 1992;89(16):7516-20
125. Kuchel JM, Barnetson RS, Halliday GM. Cyclobutane pyrimidine dimer formation is a molecular trigger for solar-simulated ultraviolet radiation-induced suppression of memory immunity in humans. Photochem Photobiol Sci 2005;4(8):577-82
126. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: A randomised study. Lancet 2001;357(9260):926-9
127. Russo PAJ, Halliday GM. Inhibition of nitric oxide and reactive oxygen species production improves the ability of a sunscreen to protect from sunburn, immunosuppression and photocarcinogenesis. Br J Dermatol 2006;155(2):408-15
128. Kuchel JM, Barnetson RS, Halliday GM. Nitric oxide appears to be a mediator of solar-simulated ultraviolet radiation-induced immunosuppression in humans. J Invest Dermatol 2003;121(3):587-93
129. Yuen KS, Halliday GM. Alpha-Tocopherol, an inhibitor of epidermal lipid peroxidation, prevents ultraviolet radiation from suppressing the skin immune system. Photochem Photobiol 1997;65(3):587-92
130. Friedmann AC, Halliday GM, Barnetson RS, et al. The topical isoflavonoid NV-07 alpha reduces solar-simulated UV-induced suppression of Mantoux reactions in humans. Photochem Photobiol 2004;80(3):416-21
131. Kuchel JM, Barnetson RSC, Zhuang L, Strickland FM, Pelley RP, Halliday GM. Tamarind inhibits solar-simulated ultraviolet radiation-induced suppression of recall responses in humans. Letters in Drug Design and Discovery 2005;2:165-71
132. Elmets CA, Singh D, Tubesing K, Matsui M, Katiyar S, Mukhtar H. Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol 2001;44(3):425-32
133. Decraene D, Smaers K, Maes D, Matsui M, Declercq L, Garmyn M. A low UVB dose, with the potential to trigger a protective p53-dependent gene program, increases the resilience of keratinocytes against future UVB insults. J Invest Dermatol 2005;125(5):1026-31
134. Motley R, Kersey P, Lawrence C. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Plast Surg 2003;56(2):85-91
135. Salasche SJ. Status of curettage and desiccation in the treatment of primary basal cell carcinoma. J Am Acad Dermatol 1984;10(2 Pt 1):285-7
136. Swetter SM, Boldrick JC, Pierre P, Wong P, Egbert BM. Effects of biopsy-induced wound healing on residual basal cell and squamous cell carcinomas: Rate of tumor regression in excisional specimens. J Cutan Pathol 2003;30(2):139-46
137. Klein E. Immunotherapeutic approaches to skin cancer. Hosp Pract 1976;11(11):107-16
138. Gutterman JU. Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci USA 1994;91(4):1198-205
139. Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990;23(4 pt 1):694-700
140. Mozzanica N, Cattaneo A, Boneschi V, Brambilla L, Melotti E, Finzi AF. Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon. Arch Dermatol Res 1990;282(5):311-7
141. Buechner SA, Wernli M, Harr T, Hahn S, Itin P, Erb P. Regression of basal cell carcinoma by intralesional interferon-Alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest 1997;100(11):2691-6
142. De Graaf YG, Kennedy C, Wolterbeek R, Collen AF, Willemze R, Bouwes Bavinck JN. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-Transplant recipients: Results of a randomized-controlled trial. J Invest Dermatol 2006;126(3):569-74
143. Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004;77(1):115-21
144. Gollnick SO, Evans SS, Baumann H, et al. Role of cyto kines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003;88(11):1772-9
145. Oseroff A. PDT as a cytotoxic agent and biological response modifier: Implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol 2006;126(3):542-4
146. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002;62(6):1604-8
147. Gupta AK, Davey V, McPhail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-Analysis of efficacy studies. J Cutan Med Surg 2005;9(5):209-14
148. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004;50(5):722-33
149. Epstein E. Fluorouracil paste treatment of thin basal cell carcinomas. Arch Dermatol 1985;121(2):207-13
150. Peris K, Micantonio T, Fargnoli MC, Lozzi GP, Chimenti S. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol 2006;55(2):324-7
151. Hengge UR, Schaller J. Successful treatment of invasive squamous cell carcinoma using topical imiquimod. Arch Dermatol 2004;140(4):404-6
152. Ooi T, Barnetson RS, Zhuang L, et al. Imiquimodinduced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: A randomized controlled trial. Br J Dermatol 2006;154(1):72-8
153. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114(1):135-41
154. O'Sullivan I, Kim TS, Chopra A, Cohen EP. Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma. Anticancer Res 2006;26(2A): 873-84
155. Zhang G, Luo X, Sumithran E, et al. Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene 2006; 25(55):7260-6